Storage and Deposition Diseases

  • Duncan A. Gordon


This chapter covers a number of unusual arthropathies that are caused by deposition of normal material, such as metal ions, or storage of abnormal material, such as lipids (1). Hemochromatosis, ochronosis, and Wilson’s disease are characterized by cellular deposition of the normal metal ions: iron, calcium, and copper, respectively. In the case of Gaucher’s disease, Fabry’s disease, Farber’s disease, and multicentric reticulohistiocytosis, rheumatic manifestations result from cellular storage of abnormal lipids. In hemochromatosis, arthralgias may be the first indication of a systemic disorder, but arthritis evolves as a predominant feature in ochronosis, Gauchers’s disease, and multicentric reticulohistiocytosis.


Synovial Fluid Iron Overload Osteochondritis Dissecans C282Y Mutation Homogentisic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rooney PJ. Hyperlipidemias, lipid storage disorders, metal storage disorders and ochronosis. Curr Opin Rheumatol 1991;3:166–171.CrossRefPubMedGoogle Scholar
  2. 2.
    Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N Engl J Med 2004;350:2383–2397.CrossRefPubMedGoogle Scholar
  3. 3.
    McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619–624.CrossRefPubMedGoogle Scholar
  4. 4.
    Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated inpatients with hereditary hemochromatosis. Nat Genet 1996;13:399–408.CrossRefPubMedGoogle Scholar
  5. 5.
    Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769–1778.CrossRefPubMedGoogle Scholar
  6. 6.
    Piperno A, Fargion S, D’Alba R, et al. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol 1992;16:364–368.CrossRefPubMedGoogle Scholar
  7. 7.
    Mathews JL, Williams HJ. Arthritis in hereditary hemochromatosis. Arthritis Rheum 1987;30:1137–1141.CrossRefPubMedGoogle Scholar
  8. 8.
    Ross JM, Kowalchuk RM, Shaulinsky J, et al. Association of heterozygous hemochromatosis C282Y gene mutation with hand osteoarthritis. J Rheumatol 2003;30:121–125.PubMedGoogle Scholar
  9. 9.
    Perry MB, Suwannarat P, Furst GP, et al. Musculoskeletal findings and disability in alkaptonuria. J Rheumatol 2006;33:2280–2285.PubMedGoogle Scholar
  10. 10.
    Fernandez-Canon JM, Grandadino B, Beltram-Valero de Bernabe D, et al. The molecular basis of alkaptonuria. Nat Genet 1996;14:19–24.CrossRefPubMedGoogle Scholar
  11. 11.
    Gaines JJ, Tom GD, Khan Khanian N. The ultrastructural and light microscopic study of the synovium in ochronotic arthropathy. Hum Pathol 1987;8:1160–1164.CrossRefGoogle Scholar
  12. 12.
    Suwannarat P, Obrien K, Perry MB, et al. Use of nitisinone in patients with alkaptonuria. Metabolism 2005;54:719–728.CrossRefPubMedGoogle Scholar
  13. 13.
    Gow PJ, Smallwood RA, Angust PW, et al. Diagnosis of Wilson’s disease: an experience over three decades. Gut 2000;46:415–419.CrossRefPubMedGoogle Scholar
  14. 14.
    Memerey KA, Eider W, Brewer GJ, et al. The arthropathy of Wilson’s disease: clinical and pathologic features. J Rheumatol 1988;15:331–337.Google Scholar
  15. 15.
    Pastores GM, Meere PA. Musculoskeletal compli-cations associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucupolysaccharidosis type 1). Curr Opin Rheumatol 2005;17:70–78.CrossRefPubMedGoogle Scholar
  16. 16.
    Grabowski GA. Enzyme therapy is not enough. Lancet 2001;358(Suppl):S29.CrossRefPubMedGoogle Scholar
  17. 17.
    Brady RO. Emerging strategies for the treatment of hereditary metabolic storage disorders. Rejuvenation Res 2006;9:237–244.CrossRefPubMedGoogle Scholar
  18. 18.
    Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry Disease: a randomized controlled trial. JAMA 2001;285:2743–2749.CrossRefPubMedGoogle Scholar
  19. 19.
    Chanoki M, Ishii M, Fukaik, et al. Farber’s lipogranulomatosis in siblings: light and electron microscopic studies. Br J Dermatol 1989;121:779–785.CrossRefPubMedGoogle Scholar
  20. 20.
    Rodey GE, et al. Defective bacteriocidel activity of peripheral blood leukocytes in lipochrome histiocytosis. Am J Med 1970;49:322–327.CrossRefPubMedGoogle Scholar
  21. 21.
    Gorman JD, Danning C, Schumacher HR, et al. Multi-centric reticulohistiocytosis: case report with immunochemical analysis and literature review. Arthritis Rheum 2000;43:930–938.CrossRefPubMedGoogle Scholar
  22. 22.
    Romas E, Finlay M, Woodruff T. The arthropathy of fibroblastic rheumatism. Arthritis Rheum 1997;40:183–187.CrossRefPubMedGoogle Scholar
  23. 23.
    Shannon SE, Schumacher HR, Self S, Brown AN. Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient. J Rheumatol 2005;32:565–567.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Duncan A. Gordon
    • 1
    • 2
  1. 1.Department of MedicineUniversity of TorontoTorontoCanada
  2. 2.University Health Network, Toronto Western HospitalTorontoCanada

Personalised recommendations